Table 4

Univariate analysis for progression free survival
Variables N Progression free survival (months) P
Median ± SE 95% CI
CypA <0.01
     Low 16 16.42 ± 1.16 17.08-21.76
     High 54 7.42 ± 0.60 6.24-8.59
MMP9 <0.01
     Low 20 16.332 ± 1.75 10.91-14.93
     High 50 7.70 ± 0.62 6.49-8.91
Age 0.220
     <65 48 11.47 ± 1.22 9.08-13.87
     ≥65 22 9.44 ± 1.23 7.03-11.84
Gender 0.950
     Male 45 10.82 ± 1.24 8.38-13.25
     Female 25 11.30 ± 1.45 8.46-14.15
Smoking 0.269
     Yes (>40 pack-years) 51 10.06 ± 1.02 8.01-12.05
     No 19 12.35 ± 1.82 8.79-15.92
Drink 0.406
     Yes (>50 ml/day) 39 11.28 ± 1.25 8.83-13.72
     No 31 10.07 ± 11.32 7.48-12.66
Differentiation <0.01
     Well + Moderate 39 13.33 ± 1.28 10.82-15.84
     Poor 31 7.07 ± 0.78 5.54-8.60
TNM stage 0.295
     I–II 22 12.02 ± 1.87 8.36-15.67
     III–IV 48 10.20 ± 1.02 8.20-12.19
Lymph node 0.041
     Metastasis 38 8.79 ± 1.20 6.44-11.14
     No metastasis 32 12.75 ± 1.20 10.40-15.10

Li et al.

Li et al. Diagnostic Pathology 2013 8:207   doi:10.1186/1746-1596-8-207

Open Data